Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer

PURPOSE: In estrogen receptor-positive (ER+) breast cancer models, activation of Aurora A kinase (AURKA) is associated with downregulation of ERα expression and resistance to endocrine therapy. Alisertib is an oral selective inhibitor of AURKA. The primary objectives of this phase I trial were to de...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Tufia C., D’Assoro, Antonino, Suman, Vera, Opyrchal, Mateusz, Peethambaram, Prema, Liu, Minetta C., Goetz, Matthew P., Ingle, James N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842248/
https://www.ncbi.nlm.nih.gov/pubmed/29289986
http://dx.doi.org/10.1007/s10549-017-4616-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842248/
https://www.ncbi.nlm.nih.gov/pubmed/29289986
http://dx.doi.org/10.1007/s10549-017-4616-7

Ejemplares similares